A5070069434- Cardiac Arrhythmias and Treatments
- Atrial Fibrillation Management and Outcomes
- Cardiac electrophysiology and arrhythmias
- Cardiac pacing and defibrillation studies
- Cardiovascular Syncope and Autonomic Disorders
- Cardiac Imaging and Diagnostics
- Receptor Mechanisms and Signaling
- Viral Infections and Immunology Research
- Cardiovascular Effects of Exercise
- Monoclonal and Polyclonal Antibodies Research
- Cardiomyopathy and Myosin Studies
- Obstructive Sleep Apnea Research
- ECG Monitoring and Analysis
- Cardiovascular Function and Risk Factors
- Health Systems, Economic Evaluations, Quality of Life
- Heart Rate Variability and Autonomic Control
- Advanced MRI Techniques and Applications
- Analytical Methods in Pharmaceuticals
- Pharmacological Effects and Assays
- Asthma and respiratory diseases
- Eicosanoids and Hypertension Pharmacology
- Neurological Disorders and Treatments
- Healthcare Systems and Public Health
- Thyroid Disorders and Treatments
- Chemical synthesis and pharmacological studies
National Medical Research Center of Cardiology
2018-2025
Rostov State Medical University
2024
Research Institute of Human Morphology
2024
Building Research Institute
2024
Russian New University
2024
Mirai Hospital
2024
Russian Scientific Center of Surgery
2024
University of Oxford
2024
Laboratoire Lorrain de Recherche en Informatique et ses Applications
2023
Research Medical Center
2023
Vitamin K antagonists are highly effective in preventing stroke patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of similar population comparison aspirin.In this randomized, double-blind trial, we compared apixaban (at dose 5 mg twice daily) warfarin (target international normalized ratio, 2.0 3.0) 18,201 and at least one additional for stroke. The primary outcome was ischemic or...
Vitamin K antagonists have been shown to prevent stroke in patients with atrial fibrillation. However, many are not suitable candidates for or unwilling receive vitamin antagonist therapy, and these a high risk of stroke. Apixaban, novel factor Xa inhibitor, may be an alternative treatment such patients.In double-blind study, we randomly assigned 5599 fibrillation who were at increased whom therapy was unsuitable apixaban (at dose 5 mg twice daily) aspirin (81 324 per day), determine whether...
Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation. It also lowers heart rate blood pressure has antiadrenergic potential ventricular antiarrhythmic effects. We hypothesized that dronedarone would reduce major vascular events high-risk permanent fibrillation.We assigned patients who were at least 65 years of age with a 6-month history fibrillation risk factors for to receive placebo. The first coprimary outcome was stroke, myocardial...
Background— During follow-up of between 1 and 3 years in the Randomized Evaluation Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses dabigatran etexilate were shown to be effective safe for prevention stroke or systemic embolism patients with atrial fibrillation. There is a need longer-term on further data comparing doses. Methods Results— Patients randomly assigned RE-LY eligible Multicenter Extension Dabigatran Treatment Atrial Fibrillation (RELY-ABLE) trial if they had not...
Russian Society of Cardiology (RSC). With the participation Scientific Clinical Electrophysiology, Arrhythmology and Cardiac Pacing, Association Cardiovascular Surgeons. Approved by Practical Council Ministry Health.
Russian Society of Cardiology, National Preventive Cardiology
<h3>Objective</h3> To compare the efficacy and safety of a single dose ibutilide, new class III antiarrhythmic drug, with that dl-sotalol in terminating chronic atrial fibrillation or flutter haemodynamically stable patients. <h3>Design</h3> Double blind, randomised study. <h3>Setting</h3> 43 European hospitals. <h3>Patients</h3> 308 patients (mean age 60 years, 70% men, 48% heart disease) sustained (n = 251) 57) (duration three hours to 45 days) were groups receive 10 minute infusion 1 mg...
Russian Society of Cardiology (RSC). With the participation Scientific Clinical Electrophysiology, Arrhythmology and Cardiac Pacing, Association Pediatric Cardiologists, for Holter Monitoring Noninvasive Electrocardiology. Approved by Practical Council Ministry Health.
Abstract In the present report we have examined expression of gene encoding inflammatory monokine TNF-alpha in murine peritoneal macrophages treated with different forms low density lipoprotein (LDL). LDL modified by oxidation vitro is unable to stimulate macrophages. However, treatment macrophage cultures oxidized for 6 h or more resulted a concentration and time-dependent suppression mRNA induced response stimulation either LPS maleylated BSA. This was maximal after 12 exposure at 100 200...
We present a clinical case of familial LMNA-associated cardiomyopathy, confirmed by whole genome sequencing. The typical for lamin-associated cardiomyopathy indicates pathogenic nature the mutation in first exon LMNA gene, previously considered unknown significance. presented demonstrates radical change patient treatment strategies context widespread introduction molecular genetic research methods into practice.
Aim. To evaluate myocardial function in different groups of patients with left bundle branch block (LBBB) and the LBBB "model" — right ventricular pacing (RVP). Material methods. Global longitudinal strain (GLS) parameters, such as global constructive work (GCW), wasted (GWW), index (GWI), efficiency (GWE), were measured 25 dilated cardiomyopathy (DCM) (DCM-LBBB group), 20 DCM a narrow QRS complex (DCM-nonLBBB 15 developed after transcatheter aortic valve implantation (TAVI 12 idiopathic...
Aim. We aimed to assess safety and effectiveness of class III antiarrhythmic drug Refralon for conversion atrial fibrillation (AFib) flutter (AFl) in post-registration trial compare data primary center (National medical research cardiology) with other hospitals. Material Methods . performed retrospective cohort study 727 patients (451 enrolled 276 hospitals) admitted between June 24, 2014 2019. was administered AFib AFl intense care units escalating doses (10-30 mcg/kg) intravenously....
Aim. We aimed to compare effectiveness of new class III antiarrhythmic drug Refralon with direct current cardioversion (DCC) in patients persistent atrial fibrillation (AF). Material and methods. 60 AF were randomized groups DCC (n=30) pharmacologic conversion (PCV; n=30). There no differences age, sex, duration, concomitant cardiovascular diseases, CHA2DS2-VASc score echocardiographic parameters between the compared. Initial assessment excluded contraindications restore sinus rhythm (SR)....
.
With the participation: All-Russian Scientific Society of Specialists in Clinical Electrophysiology, Arrhythmology and Pacing, Russian Association Cardiovascular Surgeons Endorsed by: Research Practical Council Ministry Health Federation
Chronic heart failure (CHF) and atrial fibrillation (AF) can rightly be called the epidemic of XXI century, which are associated with high morbidity mortality patients. Common risk factors pathophysiological mechanisms explain frequent combination CHF AF. So far, a number issues related to management these patients, remains unresolved. Data on compliance clinical guidelines prevalence long-term anticoagulant therapy in this group patients our country is limited. The first Russian register AF...
To evaluate the efficacy and safety of refralon (niferidil), a new class III antiarrhythmic agent whose activity is related to block delayed rectifying potassium current prolongation atrial ventricular action potential refractory periods, when it used as an for pharmacological cardioversion fibrillation (AF) flutter (AFL).The drug 3 intravenous boluses 10 μg/kg was evaluated in 134 patients (90 men; 57.8 ± 11 years) with mean AF duration (1.5; 6) months. Its effect controlled by 24-hour...
Aim: To evaluate the safety and tolerance of single dose or repeated doses administration domestic class III antiarrhythmic agent Refralon (cavutilide), tablets, by healthy volunteers; to study it’s pharmacokinetics absolute bioavailability. Material Methods. Healthy male volunteers, aged 18 – 45 years were included in one 7 cohorts: 1, 2, 4 и 6 mg PO, 1 IV (these cohorts people each), cohort 12 who took 2 drug per day for 5 days, menfor 10 days. Drug intake/injection, blood urine tests,...
Aim . To compare efficacy and safety of refralon amiodarone for cardioversion in patients with paroxysmal atrial fibrillation flutter (AF/AFL). Methods The study included 60 (32 men 28 women) symptomatic AF/AFL. All underwent a preliminary examination to exclude contraindications cardioversion. procedure pharmacological was carried out the intensive care unit. By method envelope randomization, were divided into equal groups amiodarone, 30 participants each. Both did not differ significantly...
Aim . To compare the efficacy and safety of chemical cardioversion (CCV) with refralon amiodarone in patients paroxysmal atrial fibrillation flutter (AF/AFL). Material methods Fifty five (mean age, 65±11 years) AF/AFL were included. All underwent a preliminary examination to rule out contraindications CCV. Further, randomized into groups (n=30) (n=28), respectively. CCV was carried as follows: administration doses 5-5-10-10 µg/kg at intervals 15 minutes. Patients second group intravenously...
To uncover the potential influence of microRNA-589 (miRNA-589) on cerebral ischemia-reperfusion injury (IRI) and underlying mechanism, BV2 cells were stimulated by lipopolysaccharide (LPS) or conditioned medium (CM) primary cortical neurons undergoing oxygen-glucose deprivation (OGD). Regulatory effects miRNA-589 release inflammatory factors in induced with LPS CM OGD detected quantitative real-time polymerase chain reaction (qRT-PCR) enzyme-linked immunosorbent assay (ELISA). The...